Tuttle Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Tuttle Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,481	Closed	-$242K	–	86
2017 Q1	$242K	Buy	+2,481	New	+$238K	0.29%	38
2016 Q4	–	Sell	-28,230	Closed	-$2.73M	–	66
2016 Q3	$2.73M	Buy	28,230 +17,409	+161%	+$1.66M	2.07%	10
2016 Q2	$928K	Buy	+10,821	New	+$971K	0.85%	22
2015 Q3	–	Sell	-5,385	Closed	-$662K	–	25
2015 Q2	$662K	Buy	+5,385	New	+$645K	0.49%	16

Other funds holding IBB

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Tuttle Capital Management's IBB Position: Q2 2017 in Review

Tuttle Capital Management sold out of iShares Biotechnology ETF (IBB) in Q2 2017, closing a stake of 2,481 shares — an estimated $242K sold.

Tuttle Capital Management first reported a position in IBB in Q2 2015 and held it in 4 quarters. The position peaked at $2.73M in Q3 2016. 562 funds tracked by Wall St. Rank hold IBB as of Q2 2017.

Tuttle Capital Management reported no remaining iShares Biotechnology ETF position as of Q2 2017 after selling out during the quarter.
Tuttle Capital Management sold 2,481 iShares Biotechnology ETF shares in Q2 2017, an estimated $242K.
Tuttle Capital Management first reported a position in iShares Biotechnology ETF in Q2 2015 and held it in 4 quarters.
Tuttle Capital Management's iShares Biotechnology ETF position peaked at $2.73M in Q3 2016.
562 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2017.

Based on Tuttle Capital Management's 13F filing for Q2 2017, filed 9 Aug 2017.